Related Experiment Video
Updated: Apr 17, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
13.0K
[Myasthenia gravis: past, present and future].
1Department of Neurology, Graduate School of Medical Sciences, Kyushu University.
Rinsho Shinkeigaku = Clinical Neurology
|February 13, 2015
Summary
Myasthenia gravis (MG) management has evolved, with newer treatments available. Current strategies should prioritize minimizing high-dose corticosteroid use to improve patient quality of life.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Context:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Historically, high-dose corticosteroids significantly reduced MG mortality but caused adverse effects.
- Recent discoveries include anti-MuSK and anti-Lrp4 antibodies in MG pathogenesis.
Purpose:
- To review the historical treatment of myasthenia gravis.
- To highlight the impact of high-dose corticosteroid side effects on patient quality of life.
- To advocate for a shift towards lower-dose steroid strategies in current and future MG management.
Summary:
- Myasthenia gravis (MG) treatment has advanced since its initial description.
- While corticosteroids improved survival rates, their high-dose use is linked to poor quality of life.
- Novel antibodies like anti-MuSK and anti-Lrp4 are now recognized targets in MG.
Impact:
- Reduced mortality rates in MG patients.
- Recognition of significant quality of life impairment due to corticosteroid side effects.
- A call for revised treatment paradigms focusing on steroid dose minimization for better patient outcomes.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
01:22Myasthenia Gravis ll: Pathophysiology
1
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
1
01:15Myasthenia Gravis: Diagnostic Tests
3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
01:28Disorders of the Skeletal Muscle
2.4K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.4K
01:26Chemical Synapses
12.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.8K
01:26Chemical Synapses
10.7K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.7K